SG11201509647WA - Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity - Google Patents
Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicityInfo
- Publication number
- SG11201509647WA SG11201509647WA SG11201509647WA SG11201509647WA SG11201509647WA SG 11201509647W A SG11201509647W A SG 11201509647WA SG 11201509647W A SG11201509647W A SG 11201509647WA SG 11201509647W A SG11201509647W A SG 11201509647WA SG 11201509647W A SG11201509647W A SG 11201509647WA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptides
- amino acid
- acid sequence
- reduced immunogenicity
- modified bacteriophage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361828004P | 2013-05-28 | 2013-05-28 | |
US201361828497P | 2013-05-29 | 2013-05-29 | |
PCT/US2014/039760 WO2014193935A1 (en) | 2013-05-28 | 2014-05-28 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201509647WA true SG11201509647WA (en) | 2015-12-30 |
Family
ID=51168338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201509647WA SG11201509647WA (en) | 2013-05-28 | 2014-05-28 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
Country Status (13)
Country | Link |
---|---|
US (2) | US9988444B2 (en) |
EP (1) | EP3003349B1 (en) |
JP (1) | JP2016526044A (en) |
KR (1) | KR20160010618A (en) |
CN (1) | CN105473153A (en) |
AU (1) | AU2014274253B2 (en) |
CA (1) | CA2913414A1 (en) |
EA (1) | EA030389B1 (en) |
HK (1) | HK1223285A1 (en) |
MX (1) | MX2015016263A (en) |
PH (1) | PH12015502585A1 (en) |
SG (1) | SG11201509647WA (en) |
WO (1) | WO2014193935A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2785364B1 (en) | 2011-11-29 | 2019-01-09 | Proclara Biosciences, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
DK2906235T3 (en) | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
US10722551B2 (en) * | 2014-12-03 | 2020-07-28 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal |
CN107384960B (en) * | 2017-07-25 | 2020-06-12 | 吉优诺(上海)基因科技有限公司 | Recombinant adenovirus carrying IL-17 binding molecule transgenic vector based on replication defect, construction method and application thereof |
CA3102841A1 (en) | 2018-06-15 | 2019-12-19 | Proclara Biosciences, Inc. | General amyloid interaction motif (gaim) |
WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
CN114057858B (en) * | 2020-08-10 | 2023-03-21 | 上海瑞吉康生物医药有限公司 | Polypeptides having a disaggregating effect on protein aggregation causing neurodegenerative and neurodegenerative diseases |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
DE10399023I2 (en) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-binding proteins |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
ES2199935T3 (en) | 1991-03-15 | 2004-03-01 | Amgen Inc. | PEGILATION OF POLYPEPTIDES. |
JP3068301B2 (en) * | 1992-01-08 | 2000-07-24 | 三菱電機株式会社 | Connector support and fixing mechanism in IC card |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
AU666388B2 (en) | 1992-05-26 | 1996-02-08 | Immunex Corporation | Novel cytokine that binds CD30 |
ATE319745T1 (en) | 1997-05-21 | 2006-03-15 | Biovation Ltd | METHOD FOR PRODUCING NON-IMMUNOGENIC PROTEINS |
ES2278463T3 (en) | 1998-12-08 | 2007-08-01 | Biovation Limited | METHOD TO REDUCE THE IMMUNOGENICITY OF PROTEINS. |
US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
US7189830B2 (en) | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
ATE339446T1 (en) | 2001-03-08 | 2006-10-15 | Merck Patent Gmbh | MODIFIED HUMAN GRANULOCYTE MACROPHAGE COLONIES STIMULATING FACTOR (GM-CSF) WITH REDUCED IMMUNOGENICITY |
DE10238846A1 (en) | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Active fusion proteins and processes for their production |
PL1853285T3 (en) * | 2005-02-01 | 2011-08-31 | Univ Ramot | Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia |
BRPI0707871A2 (en) | 2006-02-15 | 2011-05-10 | Ramot At Tel Aviv University | phage display vehicles, pharmaceutical composition, and methods for treating or inhibiting and diagnosing a brain disease, disorder or condition |
US20090304726A1 (en) | 2006-02-15 | 2009-12-10 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
JPWO2007114139A1 (en) | 2006-04-06 | 2009-08-13 | 文昭 内山 | Phage display with novel filamentous phage |
EP2054515B1 (en) | 2006-07-21 | 2012-01-11 | Ramot at Tel-Aviv University Ltd. | Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates |
KR101485202B1 (en) | 2006-10-11 | 2015-01-22 | 안티토페 리미티드 | T cell epitope databases |
WO2009143470A1 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
NZ592928A (en) | 2008-11-24 | 2012-12-21 | Univ Ramot | Method for treating parkinson' s disease using filamentous bacteriophage |
WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
WO2012125555A1 (en) | 2011-03-11 | 2012-09-20 | Ramot At Tel-Aviv University Ltd. | Method for treating neurodegenerative tauopathy |
EP2785364B1 (en) * | 2011-11-29 | 2019-01-09 | Proclara Biosciences, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
DK2906235T3 (en) | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
US10722551B2 (en) | 2014-12-03 | 2020-07-28 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal |
-
2014
- 2014-05-28 EA EA201592272A patent/EA030389B1/en not_active IP Right Cessation
- 2014-05-28 SG SG11201509647WA patent/SG11201509647WA/en unknown
- 2014-05-28 CN CN201480030678.2A patent/CN105473153A/en active Pending
- 2014-05-28 KR KR1020157036227A patent/KR20160010618A/en not_active Application Discontinuation
- 2014-05-28 US US14/894,272 patent/US9988444B2/en active Active
- 2014-05-28 CA CA2913414A patent/CA2913414A1/en not_active Abandoned
- 2014-05-28 JP JP2016516776A patent/JP2016526044A/en active Pending
- 2014-05-28 EP EP14737355.9A patent/EP3003349B1/en active Active
- 2014-05-28 WO PCT/US2014/039760 patent/WO2014193935A1/en active Application Filing
- 2014-05-28 MX MX2015016263A patent/MX2015016263A/en unknown
- 2014-05-28 AU AU2014274253A patent/AU2014274253B2/en active Active
-
2015
- 2015-11-16 PH PH12015502585A patent/PH12015502585A1/en unknown
-
2016
- 2016-10-05 HK HK16111571.6A patent/HK1223285A1/en unknown
-
2018
- 2018-05-04 US US15/971,362 patent/US20180251534A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2014274253B2 (en) | 2018-06-14 |
PH12015502585A1 (en) | 2016-02-29 |
EP3003349B1 (en) | 2018-12-12 |
CA2913414A1 (en) | 2014-12-04 |
EP3003349A1 (en) | 2016-04-13 |
KR20160010618A (en) | 2016-01-27 |
HK1223285A1 (en) | 2017-07-28 |
JP2016526044A (en) | 2016-09-01 |
EA030389B1 (en) | 2018-07-31 |
EA201592272A1 (en) | 2016-04-29 |
US20160115223A1 (en) | 2016-04-28 |
US20170129945A9 (en) | 2017-05-11 |
MX2015016263A (en) | 2016-04-18 |
AU2014274253A1 (en) | 2016-01-21 |
US9988444B2 (en) | 2018-06-05 |
WO2014193935A1 (en) | 2014-12-04 |
CN105473153A (en) | 2016-04-06 |
US20180251534A1 (en) | 2018-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1223285A1 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity g3p | |
HK1203820A1 (en) | Fusion polypeptides comprising mucin-domain polypeptide linkers | |
IL252426A0 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | |
HRP20180452T1 (en) | Peptides | |
PT2983704T (en) | Fusion polypeptides and vaccines | |
HK1220492A1 (en) | Recombinant polypeptide production | |
HRP20171385T1 (en) | Combinations with a backbone-cyclized peptide | |
PL3004146T3 (en) | Polypeptides with permease activity | |
HK1207866A1 (en) | Combinations with a backbone-cyclized peptide | |
EP2956160A4 (en) | Insulin secreting polypeptides | |
GB201315130D0 (en) | Peptides | |
GB201308860D0 (en) | Delivery peptides | |
GB201316660D0 (en) | Peptides | |
GB201300529D0 (en) | Recombinant polypeptide | |
GB201300381D0 (en) | Peptides |